Tekla Life Sciences Investors - Asset Resilience Ratio
Tekla Life Sciences Investors (HQL) has an Asset Resilience Ratio of 2.96% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Tekla Life Sciences Investors's Asset Resilience Ratio has changed over time. Check HQL strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tekla Life Sciences Investors's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tekla Life Sciences Investors (HQL) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.16 Million | 2.96% |
| Total Liquid Assets | $12.16 Million | 2.96% |
Asset Resilience Insights
- Limited Liquidity: Tekla Life Sciences Investors maintains only 2.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tekla Life Sciences Investors Industry Peers by Asset Resilience Ratio
Compare Tekla Life Sciences Investors's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sequoia Econ Infrastructure
LSE:SEQI |
Asset Management | 0.40% |
|
HDFC Asset Management Company Limited
NSE:HDFCAMC |
Asset Management | 0.30% |
|
Sprott Physical Silver
TO:PSLV |
Asset Management | 99.90% |
|
Groep Brussel Lambert NV
BR:GBLB |
Asset Management | 3.60% |
|
Australian Foundation Investment Company Ltd
AU:AFI |
Asset Management | 0.00% |
|
Compagnie du Cambodge
PA:CBDG |
Asset Management | 0.00% |
|
Remgro Ltd
JSE:REM |
Asset Management | 3.61% |
|
Nuvama Wealth
NSE:NUVAMA |
Asset Management | 75.96% |
Annual Asset Resilience Ratio for Tekla Life Sciences Investors (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Tekla Life Sciences Investors.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-09-30 | 3.74% | $17.23 Million | $460.58 Million | -0.04pp |
| 2023-09-30 | 3.79% | $15.24 Million | $402.60 Million | -4.16pp |
| 2022-09-30 | 7.94% | $32.94 Million | $414.73 Million | +4.73pp |
| 2021-09-30 | 3.21% | $17.17 Million | $534.19 Million | +2.19pp |
| 2020-09-30 | 1.03% | $4.97 Million | $484.17 Million | -2.08pp |
| 2019-09-30 | 3.11% | $12.03 Million | $386.98 Million | +3.11pp |
| 2018-09-30 | 0.00% | $-1.00 | $478.47 Million | 0.00pp |
| 2017-09-30 | 0.00% | $4.00 | $468.33 Million | -2.36pp |
| 2016-09-30 | 2.36% | $9.85 Million | $417.63 Million | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more